An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

about

Improving the Proteomic Analysis of Archival Tissue by Using Pressure-Assisted Protein Extraction: A Mechanistic Approach.Electroanalysis of pM-levels of urokinase plasminogen activator in serum by phosphorothioated RNA aptamer.

P2860

Q33919125-EE0DCA21-6199-483B-B86E-D7F819CE2781 Q38301482-0AC14D6A-D292-43EC-89B6-D46917978435

P2860

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

Item

http://www.wikidata.org/entity/Q41905619

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

@en

type

Item

label

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

@en

prefLabel

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

@en

P1476

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

@en

P2093

Carol B Fowler

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Mason

http://www.w3.org/2001/XMLSchema#string

Yan-Gao Man

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.

Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Tissue fractionation by hydrostatic pressure cycling technology: the unified sample preparation technique for systems biology studies.

Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.

Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response.

P304

115-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.8084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260091996

http://www.w3.org/2001/XMLSchema#string

P698

24494029

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

3909766

http://www.w3.org/2001/XMLSchema#string

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

about

P2860

P2860

An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932